The Comparative Safety of Epirubicin and Cyclophosphamide Versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial

The ELEGANT trial compared the safety of two chemotherapy regimens, epirubicin and cyclophosphamide (EC) versus docetaxel and cyclophosphamide (TC), in 275 patients with lymph node-negative, HR-positive, HER2-negative breast cancer. The study found that EC was not inferior to TC regarding the incidence of grade 3 or 4 neutropenia, with rates of 50.71% for EC and 48.15% for TC. However, the EC regimen was associated with higher rates of all-grade anemia (42.86% vs. 22.96%) and more frequent adverse events such as nausea, vomiting, hair loss, and nail changes. There was no significant difference in disease-free survival between the two treatment groups.